相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Alternate sunitinib schedules in patients with metastatic renal cell carcinoma
S. Kalra et al.
ANNALS OF ONCOLOGY (2015)
GOAL: An inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer
Sergio Bracarda et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma
Y. G. Najjar et al.
EUROPEAN JOURNAL OF CANCER (2014)
Superior Tolerability of Altered Dosing Schedule of Sunitinib with 2-Weeks-on and 1-Week-off in Patients with Metastatic Renal Cell Carcinoma-Comparison to Standard Dosing Schedule of 4-Weeks-on and 2-Weeks-off
Tsunenori Kondo et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2014)
Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules
Bradley J. Atkinson et al.
JOURNAL OF UROLOGY (2014)
Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature
Georg A. Bjarnason et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
Clinical biomarkers of response in advanced renal cell carcinoma
A. Ravaud et al.
ANNALS OF ONCOLOGY (2013)
Optimal Management of Metastatic Renal Cell Carcinoma: Current Status
Bernard Escudier et al.
DRUGS (2013)
Randomized controlled trial versus comparative cohort study in verifying the therapeutic role of lymphadenectomy in endometrial cancer
Yukiharu Todo et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single-center experience with 31 patients
Bruno Neri et al.
INTERNATIONAL JOURNAL OF UROLOGY (2013)
Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Treatment-Associated Adverse Event Management in the Advanced Renal Cell Carcinoma Patient Treated with Targeted Therapies
Alain Ravaud
ONCOLOGIST (2011)
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Brett E. Houk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
From Randomized Controlled Trials to Observational Studies
Stuart L. Silverman
AMERICAN JOURNAL OF MEDICINE (2009)
How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents
A. Ravaud
ANNALS OF ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
分享论文
